Health
Sunquest Lauded by Frost & Sullivan for Driving Efficiency and Compliance with Its Differentiated Molecular Laboratory Information Management System
Sunquest provides various interoperable products and services that work with each other to improve lab efficiency and results accuracy LONDON, March 2, 2021 /PRNewswire/ -- Based on its recent analysis of the North American laboratory information management systems (LIMS) market for molecular an...
2021-03-02 22:00
1586
Ambu Acclaimed by Frost & Sullivan for Its Groundbreaking Single-use Flexible Endoscopes
Ambu's customer-focused innovations and use of advanced technologies help the company address market needs in a wide range of applications SANTA CLARA, Calif., March 2, 2021 /PRNewswire/ -- Based on its recent analysis of the global flexible single-use endoscope market for advanced visualization...
2021-03-02 21:00
1584
Cloud-based Enterprise Imaging to Help Expedite Healthcare Providers' Journey of Enabling Better Care
SANTA CLARA, Calif., March 2, 2021 /PRNewswire/ -- Responding to the shift toward value-based care, provider M&A and consolidation, data expansion, and analytics innovations, healthcare providers are accelerating their digital transformation for greater efficiency, automation and access across cl...
2021-03-02 20:03
4616
Global Cord Blood Corporation Announces Receipt of Unsolicited Non-Binding Acquisition Proposal
HONG KONG, March 2, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that its board of directors (the "...
2021-03-02 20:00
11199
Merck and GPHL Collaborate on Business Innovation and Development in the Greater Bay Area
GUANGZHOU, China, March 2, 2021 /PRNewswire/ -- Merck, a leading science and technology company, today signed a Memorandum of Understanding (MOU) to begin strategic collaboration with Guangzhou Pharmaceutical Holdings Limited (GPHL), China's leading pharmaceutical company. The collaboration aim...
2021-03-02 18:12
3889
Cipla receives final approval for generic version of GlaxoSmithKline's IMITREX® (Sumatriptan Nasal Spray, 20 mg)
MUMBAI, India, March 2, 2021 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereinafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the United States Food and Drug...
2021-03-02 16:01
5241
Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug
STOCKHOLM, March 2, 2021 /PRNewswire/ -- Oscotec Inc. (039200: KOSDAQ), the Korean drug development company, and Beactica Therapeutics AB, the Swedish drug discovery company, today announced a new research development and licensing agreement. Oscotec and Beactica will initially jointly collaborat...
2021-03-02 15:21
1582
Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB
SYDNEY, March 2, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB (STO: OASM), an innovation-focuse...
2021-03-02 07:00
4922
INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18
Trial achieved primary and secondary efficacy endpoints among all evaluable subjects in the Phase 3 multi-center, randomized, double-blind, placebo-controlled trial VGX-3100 is the first DNA medicine to achieve efficacy endpoints in a Phase 3 clinical trial INOVIO also continues to partner with...
2021-03-02 05:05
5515
New NCCN Guidelines for Histiocytosis Clarify Best Practices for Recently-Defined Cancers
New clinical practice guidelines from National Comprehensive Cancer Network focus on workup and management for three main adult histiocytic disorders. PLYMOUTH MEETING, Pa., March 1, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers —tod...
2021-03-01 21:35
1761
BioVaxys Expanding Technology Platform To Address Emerging SARS-CoV-2 Variants
BVX-0320 and Covid-T to have capability to address UK, Brazilian and South African Virus Variants VANCOUVER, B.C., March 1, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF)("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer app...
2021-03-01 21:00
5979
Frost & Sullivan Reveals Virtual Care's Enormous Potential in the United States
The US virtual care market is expected to witness more than a seven-and-a-half-fold growth by 2025, with a CAGR of 40.4% SANTA CLARA, Calif., March 1, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis, COVID-19 Pandemic Ignites Enthusiasm for Virtual Care, finds that virtual care is the ne...
2021-03-01 20:02
1577
Merck Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
- Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care - A Phase II trial reported that xevinapant plus che...
2021-03-01 18:48
2780
TVM Capital Healthcare Exits Cambridge Medical and Rehabilitation Center for US$ 232 Million, a 4.6x Return on Capital Invested
SINGAPORE, March 1, 2021 /PRNewswire/ -- TVM Capital Healthcare, a global specialist healthcare private equity firm operating in emerging markets, announces the successful sale of its portfolio company Cambridge Medical and Rehabilitation Center ("CMRC") to UAE-based publicly traded investment c...
2021-03-01 16:18
3767
Avalon SteriTech and SoftBank Robotics Group Launch New Joint Venture to Develop and Promote Innovative Public Healthcare and Hygiene Solutions
HONG KONG, March 1, 2021 /PRNewswire/ -- Avalon SteriTech Limited ("Avalon") and SoftBank Robotics Group ("SBRG") today announced a joint venture focusing on the development of innovative products and technologies that strive to empower and benefit public health and well-being. The joint venture ...
2021-03-01 13:00
2086
Everest Medicines Announces Selection as a Constituent of Certain Indexes of Hang Seng Indexes Company Limited
SHANGHAI, March 1, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater China and other parts of Asia, today announced t...
2021-03-01 12:36
5434
Sciwind's Investigational New Drug Approved for NASH Trial
HANGZHOU, China, March 1, 2021 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd., (Sciwind), a clinical-stage, fast-growing biotech focusing on research and development of innovative biologics, today announced that XW003, a potential candidate for the treatment of non-alcoholic steatohepatit...
2021-03-01 09:00
3309
Innovent Announces First Patient Outside China Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody
SAN FRANCISCO and SUZHOU, China, March 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2021-03-01 08:23
7374
Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index
SHANGHAI and HONG KONG, March 1, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...
2021-03-01 08:00
3159
Sirtex Medical receives positive recommendation from National Institute for Health and Care Excellence (NICE) for selective internal radiation therapy (SIRT) using SIR-Spheres®
NICE recommends SIR-Spheres® Y-90 microspheres as an option for treating unresectable advanced hepatocellular carcinoma (HCC) in adults WOBURN, Mass., Feb. 26, 2021 /PRNewswire/ -- Sirtex Medical US Holdings, Inc. ("Sirtex"), a leading manufacturer of targeted cancer therapies, received positive...
2021-02-26 23:37
2941
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 285 media titles]
2025-12-10 16:00
Asia Pacific Defies Global Headwinds: Mastercard Economics Institute 2026 Outlook
[Picked up by 277 media titles]
2025-12-10 09:00